10x Genomics, Inc. — Director's Dealing 2021

Jun 10, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2021-06-08

Reporting Person: Saxonov Serge (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-04	Class A Common Stock	G	200	$0.00	Disposed	904068	Direct
2021-06-08	Class A Common Stock	M	5209	$5.04	Acquired	909277	Direct
2021-06-08	Class A Common Stock	M	9791	$11.48	Acquired	919068	Direct
2021-06-08	Class A Common Stock	S	600	$184.1717	Disposed	918468	Direct
2021-06-08	Class A Common Stock	S	2200	$185.0468	Disposed	916268	Direct
2021-06-08	Class A Common Stock	S	4600	$185.8854	Disposed	911668	Direct
2021-06-08	Class A Common Stock	S	5239	$186.9137	Disposed	906429	Direct
2021-06-08	Class A Common Stock	S	2361	$187.9154	Disposed	904068	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-08	Stock Option (right to buy)	$5.04	M	5209	Disposed	2028-11-02	Class A Common Stock (5209)	Direct
2021-06-08	Stock Option (right to buy)	$11.48	M	9791	Disposed	2029-05-10	Class A Common Stock (9791)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Class A Common Stock	89960	Indirect

Footnotes

F1: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.

F2: This transaction was executed in multiple trades at prices ranging from $183.43 to $184.42. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3: This transaction was executed in multiple trades at prices ranging from $184.45 to $185.43. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F4: This transaction was executed in multiple trades at prices ranging from $185.45 to $186.40. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F5: This transaction was executed in multiple trades at prices ranging from $186.465 to $187.46. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F6: This transaction was executed in multiple trades at prices ranging from $187.49 to $188.31. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F7: The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.

F8: This option, originally for 250,000 shares, of which 165,427 have been exercised, vested as to one forty-eighth of the shares on October 1, 2018, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

F9: This option, originally for 145,786 shares, of which 58,281 have been exercised, vested as to one forty-eighth of the shares on May 1, 2019, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.